Articles

Avís: Els articles científics que podeu trobar a continuació tenen l’accés restringit a causa de les polítiques de propietat intel·lectual. En el llistat podeu trobar l’enllaç al cercador bibliogràfic PubMed des del qual podreu consultar els abstracts dels articles i on trobareu un enllaç directe a la revista. Així doncs, si teniu una subscripció vàlida a les revistes, feu clic a l’enllaç DOI per arribar a la revista i descarregar una còpia dels documents.

Parameter estimates for trends and patterns of excess mortality among persons on ART in high-income european settings, AIDS, 2019 Nov 19.

Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIV-positive individuals, Statistics in medicine, 2019 Jun 15;38(13):2428-2446.

Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort, HIV Medicine, 2019 Mar;20(3):237-247.

Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis, Journal of Viral Hepatitis, 2019 Oct;26(10):1224-1228.

Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples, American Journal of Epidemiology, 2019 Aug 1;188(8):1569-1577.

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?, HIV Med., 2018 Jan;19(1):42-48.

Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions, J Acquir Immune Defic Syndr.,2018 Jan 1;77(1):102-109.

Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation, J Int AIDS Soc,2018 Jan;21(1)

Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection, HIV Med, 2018 Feb;19(2):132-142.

Estimating the HIV undiagnosed population in Catalonia, Spain: descriptive and comparative data analysis to identify differences in MSM stratified by migrant and Spanish-born population., BMJ open 8.2, 2018 Feb 28;8(2):e018533

Determinants and Outcomes of Late Presentation of HIV Infection in Migrants in Catalonia, Spain: PISCIS Cohort 2004–2016, Journal of immigrant and minority health, 2018 Oct; 30: 1-11

Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older, J Acquir Immune Defic Syndr,2017;76(3):311–8.

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Int J Epidemiol,2017 Jun 1;46(3):797-797n.

Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients, HIV Med,2017 Jan;18(1):33-44.

Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe, AIDS,2017 Mar 27;31(6):835-846.

Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study, Ann Intern Med,2017 Jan 3;166(1):9-17.

Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe, HIV Med.,2017 Mar;18(3):171-180.

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers, PLoS One,2017 Apr 5;12(4):e0173893.

Is response to anti-hepatitis C virus treatment predictive of mortality in hepatitis C virus/HIV-positive patients?, AIDS,2017 Mar 13;31(5):661-668.

Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe, AIDS,2017 Jan 14;31(2):253-262.

Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study, Lancet HIV,2017 Jun;4(6):e251-e259.

Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study, Clin Infect Dis.,2017 Oct 15;65(8):1316-1326.

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies, Lancet HIV, 2017 Aug;4(8):e349-e356

Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis, AIDS,2016 Jan 28;30(3):503-13.

Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen, J Antimicrob Chemother,2016 May;71(5):1352-60.

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection, Clin Infect Dis,2016 Jun 15;62(12):1578-85.

When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study, J Acquir Immune Defic Syndr,2016 Jun 1;72(2):214-21.

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals, Medicine (Baltimore),2016 Oct;95(41):e5133.

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia, Clin Infect Dis,2016 Nov 1;63(9):1245-1253.

Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy, Int J Epidemiol,2016 Dec 1;45(6):2038-2049.

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults, AIDS,2015 Jan 14;29(2):193-200.

Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US, Antivir Ther,2015;20(1):21-8.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries, Clin Infect Dis,2015 Apr 15;60(8):1262-8.

Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients, AIDS,2015 Jan 28;29(3):373-83.

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration, J Acquir Immune Defic Syndr,2015 Jul 1;69(3):348-54.

Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013, Euro Surveill,2015 Nov 26;20(47).

Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study, Lancet HIV,2015 Dec;2(12):e540-9.

Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status, J Antimicrob Chemother,2015 Dec;70(12):3332-8.

omparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study, Lancet HIV,2015 Aug;2(8):e335-43.

Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord, BMC Infect Dis,2015 Nov 4;15:498.

The continuum of HIV care in Catalonia, AIDS Care,2015 Dec;27(12):1449-54.

Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America, AIDS,2015 Jan 14;29(2):221-9.

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries, J Acquir Immune Defic Syndr,2014 Jan 1;65(1):e8-16.

Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC), Int J Epidemiol,2014 Jun;43(3):691-702.

ong-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery, Clin Infect Dis,2014 May;58(9):1312-21.

Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions, Neurology,2014 Jul 8;83(2):134-41.

Factors associated with short-term changes in HIV viral load and CD4(+) cell count in antiretroviral-naive individuals, AIDS,2014 Jun 1;28(9):1351-6.

Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients, Clin Infect Dis,2014 Jul 15;59(2):287-97.

Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries, AIDS,2014 Oct 23;28(16):2461-73.

Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord, AIDS,2014 Sep 24;28(15):2297-306.

Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies, PLoS Med,2014 Sep 9;11(9):e1001718.

Low Prevalence of Cervical Cancer Screening Among HIV-Positive Women in Catalonia, J Aids Clin Res,2013 S3: 004.

Predictors of CD4+ T-Cell Counts of HIV Type 1-Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes, J Infect Dis,2013 Mar;207(5):759-67.

Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis, AIDS,2013 May 15;27(8):1321-9.

Influence of geographical origin and ethnicity on mortality in patients on antiretroviral therapy in Canada, Europe and the United States, Clin Infect Dis,2013 Jun;56(12):1800-9.

Insurability of HIV positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies, AIDS,2013 Jun 19;27(10):1641-55.

Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort, Clin Microbiol Infect,2013 Jul;19(7):646-53.

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE), PLoS Med,2013 Sep;10(9):e1001510.

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era, Clin Infect Dis,2013 Oct;57(7):1038-47.

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009, AIDS,2013 Mar 13;27(5):803-13.

The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis, HIV Med,2012 Feb;13(2):89-97.

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study, Lancet Infect Dis,2012 Feb;12(2):119-27.

CD4 cell count and the risk of AIDS or death in HIV infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE, PLoS Med,2012 Mar;9(3):e1001194.

Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug experienced people with HIV in Europe, J Acquir Immune Defic Syndr,2012 Mar 1;59(3):294-9.

All-cause mortality in treated HIV-infected adults with CD4 ≥500 /mm3 compared with the general population: evidence from a large European observational cohort collaboration, Int J Epidemiol,2012 Apr;41(2):433-445.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries, Clin Infect Dis,2012 May;54(9):1364-72.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study, AIDS,2012 Aug 24;26(13):1691-705.

Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration, Antivir Ther,2012;17(8):1541-50.

Human Papillomavirus Infection in HIV-1 Infected Women in Catalonia (Spain): Implications for Prevention of Cervical Cancer, PLoS One,2012;7(10):e47755.

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics, Int J Epidemiol,2012 Dec; 41(6):1807-20.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries. an observational study. An observational study, Ann Intern Med,2011 Apr 19;154(8):509-15.

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study, Lancet Infect Dis,2011 May;11(5):363-71.

Risk of triple-class virological failure in children with HIV: a retrospective cohort study, Lancet,2011 May 7;377(9777):1580-7.

HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T cell lymphocytes, Blood,2011 Jun 9;117(23):6100-8.

Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula, Stat Biosci,2011 Sep 1;3(1):119-143.

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study, J Acquir Immune Defic Syndr,2011 Nov 1;58(3):253-60.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals, AIDS,2010 Jan; 24(1):123-37.

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years, Arch Intern Med,2010 Mar 8;170(5):410-9.

Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996 – 2006: collaborative analysis of 13 HIV cohort studies, Clin Infect Dis,2010 May 15;50(10):1387-96.

Death rates in HIV-positive antiretroviral-naive patients with with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study, Lancet,2010 Jul 31;376(9738):340-5.

Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/mL?, Clin Infect Dis,2010 Sep 1;51(5):611-9.

Tractament antiretroviral de les persones que viuen amb el VIH a Catalunya. Dades de la Cohort PISCIS, 1998-2006, Infosida,2009; 39.

Incidence and risk factors of HIV-associated non-Hodgkin lymphoma in the era of combination antiretroviral therapy. European multi-cohort study, Antivir Ther,2009;14(8):1065-74.

Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy. Not All AIDS-Defining Conditions Are Created Equal, Clin Infect Dis,2009 Apr 15;48(8):1138-51.

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1 infected people: a collaborative analysis of 18 HIV cohort studies, Lancet,2009 Apr. 18;373(9672):1352-63.

Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries, Int J Epidemiol,2009 Sep 24; 38:1624-33.

Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements, AIDS,2009 Oct 23;23:2199-208.

Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression, J Acquir Immune Defic Syndr,2009 Nov. 1;52(3):357-63.

Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy, AIDS,2009 Sep 24;23(15):2029-37.

Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy. PISCIS Cohort (Spain), J Acquir Immune Defic Syndr,2008 Feb 1;47(2):212-20.

DOI: #

Does short-term virologic failure translate to clinical events in ARV-naïve patients initiating ART in clinical practice?, AIDS,2008 Nov 30;22(18):2481-92.

HIV-1 infected patients older than 50 years. PISCIS cohort study, J Infect,2008 Jul;57(1):64-71.

Life expectancy of individuals on combination antiretroviral therapy in high-income countries. A collaborative analysis of 14 cohort studies, Lancet,2008 Jul 26;372(9635):293-9.

Response to combination antiretroviral therapy: variation by age, AIDS,2008 Jul 31;22(12):1463-73.

Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies, Antivir Ther,2008;13(8):959-67.

DOI: #

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries, Clin Infect Dis,2007 Dec 1;45(11):1518-21.

Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1 infected patients, J Acquir Immune Defic Syndr,2007 Dec 15;46(5):607-15.

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies, AIDS,2007 May 31;21(9):1185-97.

Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral previo (CoRIS): metodología y primeros resultados, Enferm Infecc Microbiol Clin,2007;25(1):23-31.

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis, Lancet,2006 Aug 5;368(9534):451-8.

Características clinicoepidemiológicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infección por el virus de la inmunodeficiencia humana. Cohorte PISCIS, Med Clin (Barc),2005;124(14):525-31.

Coinfecció per VIH i pels virus de les Hepatitis B i C. Cohort PISCIS, Infosida,2005; 31.